NASDAQ: AKTSAktis Oncology Inc Stock
$17.37+0.30 (+1.76%)
Updated Apr 2, 2026
AKTS Price
$17.37
Fair Value Price
N/A
Market Cap
$927.61M
52 Week Low
$14.72
52 Week High
$29.16
P/E
-0.22x
P/B
-6.35x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$6.50M
Earnings
-$63.73M
Gross Margin
100%
Operating Margin
-980.93%
Profit Margin
-980.9%
Debt to Equity
-0.53
Operating Cash Flow
-$64M
Beta
2.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AKTS Overview
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AKTS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AKTS
Ranked#67 of 462
Ranked#67 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $186.95 | A | |
| $16.62 | A | |
| $22.99 | A |
Be the first to know about important AKTS news, forecast changes, insider trades & much more!
AKTS News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKTS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AKTS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AKTS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AKTS due diligence checks available for Premium users.
Valuation
AKTS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
28.69x
Market
30.12x
AKTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.35x
Industry
4.77x
AKTS's financial health
Profit margin
Revenue
$1.9M
Net Income
-$15.1M
Profit Margin
-809.5%
AKTS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AKTS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$264.9M
Liabilities
$77.6M
Debt to equity
-0.53
AKTS's short-term assets ($230.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKTS's short-term assets ($230.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AKTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.2M
Investing
-$126.5M
Financing
-$772.0k
AKTS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKTS vs Biotech Stocks
Aktis Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.